PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy
Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…Effects of multi-session repetitive transcranial magnetic stimulation on performance of motor control and dynamics of spontaneous brain activity in multiple system atrophy
Objective: To explore the effectiveness of repetitive transcranial magnetic stimulation (rTMS) on performance of motor control and dynamics of spontaneous brain activity in multiple system…Caregiver Burden in a Multidisciplinary MSA Clinic
Objective: To explore the correlation between disease and caregiver burden in MSA. Background: For patients with Multiple System Atrophy (MSA), the increasing loss of independence…Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure
Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations
Objective: To present the detailed clinical features of a patient with familial MSA carrying compound heterozygous COQ2 mutations and report the outcome of a high-dose ubiquinol…PROMESA: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach – evaluation of serious adverse events
Objective: In the PROMESA trial (ClinicalTrials Identifier: NCT02008721) Epigallocatechingallate (EGCG) a catechine that prevents pathological protein aggregation in vitro and can be purified from green…Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial
Objective: To explore intrathecal administration of autologous mesenchymal stem cells (MSCs) as therapeutic approach to multiple system atrophy (MSA). Background: MSA is a rapidly progressive…Systematic literature review of droxidopa in clinical trials for neurogenic orthostatic hypotension (nOH) in parkinsonism
Objective: The aim of this study was to review the published evidence for the efficacy, safety, and dosing practices of droxidopa treatment for symptomatic neurogenic…Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy
Objective: To assess the therapeutic efficacy of the caspase-1 inhibitor prodrug VX-765 on alpha-synuclein (α-syn) pathology and neuroprotection in a transgenic mouse model of multiple…Glucagon-like peptide 1 analogues for treating multiple system atrophy: A translational study
Objective: (i) To determine whether insulin resistance is a neuropathological feature of multiple system atrophy (MSA) and, (ii), to evaluate the therapeutic efficacy of the…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »